Key Takeaways AMN expects Q3 Nurse and Allied Solutions revenues to rise 9-11% as staffing demand strengthens.MSP arrangements generated about 46% of AMN Healthcare's consolidated revenues in Q2'26.AMN is expanding AI-enabled language, leadership and workforce tools to diversify beyond staffing. AMN Healthcare Services, Inc. (AMN - Free Report) is well-poised for growth in the coming quarters, courtesy of its broad array of services. The optimism is led by strong momentum in its Managed Services Program (MSP), favorable healthcare staffing demand, diversified workforce solutions, and investments in technology and AI-driven platforms. However, stiff competition, industry regulations and changing marketplace conditions are major downsides.
Shares of this Zacks Rank #3 (Hold) company have skyrocketed 114.5% year to date against the industry's 12% decline. However, the S&P 500 Index has risen 12.2% in the said timeframe.
This renowned player in the healthcare total talent services space has a market capitalization of $1.31 billion. The company projects 144.1% year-over-year earnings growth for 2026 and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in the trailing four quarters, delivering an average earnings surprise of 96.63%.
Image Source: Zacks Investment Research
Factors Favoring AMN StockFavorable Healthcare Staffing Demand: Demand for healthcare staffing remains supported by population growth, aging demographics, increasing care complexity and persistent labor shortages. Healthcare providers are increasingly using flexible workforce models and external staffing partners to manage labor variability and improve efficiency.
In second-quarter 2026, travel nurse volume increased 6% year over year, while allied volume rose 7%, the strongest growth rates in four years. Travel nurse orders turned positive in May and reached approximately 40% growth by early August, while allied orders grew in the mid-teens during June and July. Management expects more than 10% year-over-year growth in both businesses in the third quarter and forecasts Nurse and Allied Solutions revenue growth of 9-11%. Sustained demand could drive stronger staffing volumes and support AMN’s revenue recovery.
Expanding MSP Penetration: AMN Healthcare’s Managed Services Programs (MSPs) strengthen client relationships by helping providers manage supplemental labor across AMN and third-party suppliers. MSP arrangements accounted for approximately 46% of consolidated revenues in second-quarter 2026. In 2025, AMN managed $1.8 billion of spend through MSPs and $3.3 billion, including vendor-neutral programs. Broad-based demand across regions, provider sizes and service models further supports the platform’s workforce optimization capabilities. The scale of AMN’s MSP platform provides recurring access to large healthcare staffing demand and strengthens client retention while creating opportunities to capture additional market share.
Diversified Workforce Solutions: AMN has expanded beyond traditional staffing into technology-enabled total talent solutions spanning staffing, recruitment, MSP, Vendor Management Systems (VMS), language services, consulting and workforce optimization. Second-quarter growth included travel nurse, allied and international nurse staffing, while physician search increased new searches 40% year over year and executive search rose 30%.
AMN also expanded its WorkWise platform with supplier and rate intelligence, while Passport users surpassed 400,000. In June 2026, the company acquired Jaide Health to enhance AI-enabled language interpretation and ESSENTIAL Leadership Assessment to expand leadership evaluation, coaching and succession planning capabilities. This broad service portfolio creates multiple avenues for growth beyond traditional healthcare staffing.
Downsides of AMN StockStiff Competition: AMN Healthcare operates in a highly competitive staffing and workforce-solutions market, with pressure from national, regional and specialized providers. Locum tenens demand is increasingly shifting toward vendor-neutral channels, which management describes as highly competitive. Language services revenues also declined as pricing per minute fell 8%, while Technology and Workforce Solutions revenues dropped 15% year over year. Continued competition could limit pricing power, fill rates and revenue growth.
Changing Marketplace Conditions: Healthcare providers continue to adjust staffing models and focus on controlling labor costs. Contingent labor premiums have fallen to the mid- to high-single digits from the mid- to high-teens before COVID-19, indicating a normalization of pandemic-era economics. Although Nurse and Allied demand is recovering, third-quarter 2026 consolidated revenue guidance calls for only 1-3% year-over-year growth as declines in other segments offset staffing gains. These market shifts could slow AMN’s overall recovery.
Healthcare Industry Regulations: Regulatory and administrative changes can affect clinician availability, client demand and international staffing. AMN’s international nurse business benefited from forward movement in visa cutoff dates, but embassy appointment backlogs remain a constraint. Management indicated that resolving these delays will influence international growth in 2027. Changes in immigration policies or continued processing delays could therefore create staffing shortages, delay placements and increase operating uncertainty.
Estimate TrendAMN Healthcare has been witnessing a positive estimate revision trend for 2026. Over the past 60 days, the Zacks Consensus Estimate for its earnings per share has improved 22.9% to $3.32.
The Zacks Consensus Estimate for third-quarter 2026 revenues and earnings per share is pegged at $648 million and 22 cents, respectively, suggesting 2.1% growth and a 43.6% decline from the year-ago reported numbers.
Key PicksSome better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
, /PRNewswire/ -- ONE Gas, Inc. (NYSE: OGS) today announced it will participate in the American Gas Association Mini-Forum, September 15, 2026, in Boston.
Christopher Sighinolfi, senior vice president and chief financial officer, and Mark Smith, vice president and treasurer, will be conducting a series of meetings with members of the investment community.
The materials utilized at the conference will be accessible on the ONE Gas website, www.onegas.com/investors/events-and-presentations.
ONE Gas, Inc. (NYSE: OGS) is a 100-percent regulated natural gas utility, and trades on the New York Stock Exchange and the NYSE Texas under the symbol "OGS." ONE Gas is included in the S&P MidCap 400 Index and is one of the largest natural gas utilities in the United States.
Headquartered in Tulsa, Oklahoma, ONE Gas provides a reliable and affordable energy choice to more than 2.3 million customers in Kansas, Oklahoma and Texas. Its divisions include Kansas Gas Service, the largest natural gas distributor in Kansas; Oklahoma Natural Gas, the largest in Oklahoma; and Texas Gas Service, the third largest in Texas, in terms of customers.
For more information and the latest news about ONE Gas, visit onegas.com and follow its social channels: @ONEGas, Facebook, Linkedln and YouTube.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.
That's where the Style Scores come in.
You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Strategic Education (STRA - Free Report) Strategic Education or SEI, is an education services company that provides campus-based and online post-secondary education, along with programs designed to build job-ready skills for high-demand markets. Its higher education institutions are Capella University and Strayer University in the United States and Torrens University in Australia. The company primarily serves working adult students.
STRA is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.
Momentum investors should take note of this Consumer Discretionary stock. STRA has a Momentum Style Score of B, and shares are up 0.2% over the past four weeks.
For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $7.23 per share. STRA boasts an average earnings surprise of +9%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, STRA should be on investors' short list.
In the latest trading session, Oneok Inc. (OKE - Free Report) closed at $97.51, marking a +2.18% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.58%. Meanwhile, the Dow lost 1.18%, and the Nasdaq, a tech-heavy index, lost 0.32%.
The stock of natural gas company has risen by 5.63% in the past month, lagging the Oils-Energy sector's gain of 6.77% and overreaching the S&P 500's loss of 0.36%.
Analysts and investors alike will be keeping a close eye on the performance of Oneok Inc. in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.49, indicating constancy compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $11.77 billion, indicating a 36.34% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $5.75 per share and a revenue of $43.77 billion, demonstrating changes of +6.09% and +30.16%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Oneok Inc. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.47% lower within the past month. Oneok Inc. currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Oneok Inc. currently has a Forward P/E ratio of 16.59. This expresses a premium compared to the average Forward P/E of 14.59 of its industry.
Meanwhile, OKE's PEG ratio is currently 2.7. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. OKE's industry had an average PEG ratio of 2.06 as of yesterday's close.
The Oil and Gas - Production Pipeline - MLB industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 51, which puts it in the top 21% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Shares of Green Thumb Industries Inc. (GTBIF - Free Report) have gained 10.1% over the past four weeks to close the last trading session at $7.68, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.61 indicates a potential upside of 103.3%.
The average comprises seven short-term price targets ranging from a low of $10.00 to a high of $18.38, with a standard deviation of $2.94. While the lowest estimate indicates an increase of 30.2% from the current price level, the most optimistic estimate points to a 139.3% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for GTBIF, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in GTBIFAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Over the last 30 days, the Zacks Consensus Estimate for the current year has increased 5.3%, as one estimate has moved higher compared to no negative revision.
Moreover, GTBIF currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much GTBIF could gain, the direction of price movement it implies does appear to be a good guide.
QuoteMedia (OTCMKTS:QMCI – Get Free Report) and Getty Images (NYSE:GETY – Get Free Report) are both small-cap communication services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.
Valuation & Earnings This table compares QuoteMedia and Getty Images”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio QuoteMedia $20.25 million 0.69 -$2.32 million ($0.02) -7.75 Getty Images $981.29 million 0.11 -$206.12 million ($0.39) -0.66 QuoteMedia has higher earnings, but lower revenue than Getty Images. QuoteMedia is trading at a lower price-to-earnings ratio than Getty Images, indicating that it is currently the more affordable of the two stocks. Analyst Recommendations This is a summary of current recommendations and price targets for QuoteMedia and Getty Images, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QuoteMedia 0 1 0 0 2.00 Getty Images 1 3 1 0 2.00 Getty Images has a consensus target price of $3.92, suggesting a potential upside of 1,427.24%. Given Getty Images’ higher possible upside, analysts plainly believe Getty Images is more favorable than QuoteMedia.
Insider and Institutional Ownership 45.8% of Getty Images shares are held by institutional investors. 47.1% of QuoteMedia shares are held by company insiders. Comparatively, 9.3% of Getty Images shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability This table compares QuoteMedia and Getty Images’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets QuoteMedia -9.06% N/A -34.83% Getty Images -16.24% -26.82% -5.25% About QuoteMedia (Get Free Report)
QuoteMedia, Inc. provides financial data, market research information, analytics, news feeds, and financial software solutions to online brokerages, banks, clearing firms, financial service companies, media portals, and public corporations worldwide. It collects, aggregates, and delivers delayed and real-time financial data content through the Internet. The company also offers market information and services, including streaming stock market data feeds, research and analysis information, content applications, portfolio management systems, software products, corporate investor relations provisioning, news services, mobile apps, and custom development. In addition, its data feeds coverage includes equities, options, futures, commodities, currencies, mutual funds, ETFs, and indices. Further, the company provides financial data delivery application products and components comprising quote modules, charts, market movers, news, watch lists, tickers, market summaries, option chains, filings, fundamentals, investor relations solutions, stock and fund screeners, and others; and QMod, a web delivery system for delivering market data content to Web platforms. Additionally, it offers portfolio managements systems, including Quotestream Desktop, We, and Mobile, a Web-delivered, embedded application providing real-time, tick-by-tick, streaming market quotes and research information; Quotestream Professional that offers low-latency tick-by-tick data, customizable screens, advanced charting, comprehensive technical analysis, news, and research data for financial services professionals; Web Portfolio Manager, which provides immediate web access to detailed quote data, market and company news, charting, depth/level II, filings, historical data, snap quotes, and others; and Quotestream Connect that delivers real time data feeds to individual users to power third party applications. The company was incorporated in 1992 and is headquartered in Fountain Hills, Arizona.
About Getty Images (Get Free Report)
Getty Images Holdings, Inc. offers creative and editorial visual content solutions in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Its products include Getty Images that offers creative and editorial content including stills, music and video which focuses on corporate, agency, and media customers; iStock.com, an e-commerce offering where customers have access to creative stills and video; Unsplash.com, a platform offering free stock photo downloads and paid subscriptions targeted to the high-growth prosumer and semi-professional creator segments; and Unsplash+ that provides access to unique model released content with expanded legal protections. In addition, it maintains privately-owned photographic archives covering news, sport, and entertainment, as well as variety of subjects, including lifestyle, business, science, health, wellness, beauty, sports, transportation, and travel. Further, the company provides music licensing, and digital asset management and distribution services. It serves media outlets, advertising agencies and corporations, individual creators, and prosumers. The company was formerly known as Getty Images, Inc. Getty Images Holdings, Inc. was founded in 1995 and is headquartered in Seattle, Washington.
Receive News & Ratings for QuoteMedia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuoteMedia and related companies with MarketBeat.com's FREE daily email newsletter.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether OSI and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On August 20, 2026, OSI reported fiscal fourth-quarter and full-year 2026 financial results, including revenue that fell short of consensus expectations. OSI attributed the revenue miss to deferred product deliveries stemming from site constraints.
On this news, OSI’s stock price fell $11.36 per share, or 5.21%, to close at $206.73 per share on August 21, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
NEW YORK--(BUSINESS WIRE)---- $OSIS #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On August 20, 2026, OSI reported its fourth quarter 2026 and full-year 2026 financial results, revealing fourth q.
OSIS SHAREHOLDER ALERT: OSI Systems, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
[LEARN MORE ABOUT THE INVESTIGATION]
What Happened?
On August 20, 2026, OSI reported its fourth quarter 2026 and full-year 2026 financial results, revealing fourth quarter revenue that fell short of analysts’ expectations by 8.5%, with sales falling 4.1% year-on-year to $484.1 million. The Company attributed the revenue shortfall to Security division delivery disruptions caused by conflicts in the Middle East, stating, “these results were affected by the timing of approximately $50 million of planned Security deliveries that moved beyond our June 30th fiscal year-end because of conflict-related delays and site access constraints in the Middle East.” On this news, OSI’s stock price fell $11.36, or 5.21%, to close at $206.73 per share on August 21, 2026.
What Should I Do?
At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.
If you purchased or otherwise acquired OSI securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.
[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260908654634/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin May Receive a Freely Tradable Priority Review Voucher (PRV)Quoin Expects to Initiate Phase 2 Study in 2H 2026; Study Plans to Enroll up to 12 Pediatric and Adult Peeling Skin Patients in the U.S. and EuropeThere are Currently No Approved Treatments for Peeling Skin Syndrome ASHBURN, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company’s lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS).
The designation reinforces the potential of QRX003 as a therapeutic candidate for a profoundly underserved pediatric population. This is the second RPD designation granted for QRX003, following the previously granted RPD designation for Netherton Syndrome.
The FDA’s Rare Pediatric Disease Designation program is intended to encourage the development of new therapies for serious and life-threatening diseases that primarily affect individuals under 18 years of age. If a New Drug Application (NDA) for QRX003 is approved, Quoin may qualify to receive a Priority Review Voucher (PRV), which can be redeemed to receive priority review for another marketing application or may be sold or transferred.
“We are very pleased to announce the receipt of Rare Pediatric Disease Designation for QRX003 for Peeling Skin Syndrome,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “With the IND cleared by FDA, the Quoin team is preparing to initiate the Phase 2 clinical study before the end of this year with plans to enroll up to 12 pediatric and adult Peeling Skin patients in the U.S. and Europe. This will be the first formal study ever conducted in the U.S. for this disease under an open IND.”
About Peeling Skin Syndrome (PSS)
Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin's innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “look forward to,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential of QRX003 as a therapeutic candidate for Peeling Skin Syndrome and a profoundly underserved pediatric population, Quoin’s eligibility to receive Priority Review Vouchers upon approval of a New Drug Application for QRX003; the initiation of a Phase 2 clinical study for Peeling Skin Syndrome before the end of 2026 with plans to enroll up to 12 pediatric and adult patients in the U.S. and Europe; and Quoin’s belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO [email protected]
Investor Relations
PCG Advisory
Jeff Ramson [email protected]
(646) 863-6341
Hsbc Holdings PLC lifted its position in shares of Tetra Tech, Inc. (NASDAQ:TTEK – Free Report) by 45.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 628,625 shares of the industrial products company’s stock after purchasing an additional 197,653 shares during the quarter. Hsbc Holdings PLC owned approximately 0.25% of Tetra Tech worth $17,955,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new position in Tetra Tech in the fourth quarter worth $115,162,000. Energy Income Partners LLC bought a new position in shares of Tetra Tech during the 2nd quarter worth about $68,512,000. AQR Capital Management LLC lifted its holdings in shares of Tetra Tech by 351.6% during the 4th quarter. AQR Capital Management LLC now owns 2,875,372 shares of the industrial products company’s stock worth $96,440,000 after acquiring an additional 2,238,721 shares during the period. Bank of America Corp DE acquired a new stake in shares of Tetra Tech during the 2nd quarter valued at about $57,135,000. Finally, Capital International Investors increased its stake in Tetra Tech by 27.4% in the fourth quarter. Capital International Investors now owns 9,016,577 shares of the industrial products company’s stock valued at $302,416,000 after acquiring an additional 1,936,902 shares during the period. 93.89% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets Several research analysts recently issued reports on TTEK shares. National Bank Financial dropped their price target on shares of Tetra Tech from $38.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Wall Street Zen lowered Tetra Tech from a “buy” rating to a “hold” rating in a research note on Saturday, August 22nd. Royal Bank Of Canada dropped their target price on Tetra Tech from $48.00 to $43.00 and set an “outperform” rating for the company in a report on Wednesday, July 22nd. Weiss Ratings upgraded Tetra Tech from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 7th. Finally, Robert W. Baird set a $37.00 price target on Tetra Tech in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.25.
Check Out Our Latest Stock Report on TTEK Tetra Tech Trading Down 0.8% Shares of NASDAQ TTEK opened at $35.64 on Wednesday. Tetra Tech, Inc. has a 1-year low of $25.81 and a 1-year high of $43.14. The company has a 50-day moving average of $33.79 and a two-hundred day moving average of $31.64. The company has a market cap of $9.13 billion, a PE ratio of 21.47 and a beta of 0.90. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.43.
Tetra Tech (NASDAQ:TTEK – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The industrial products company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.40 by $0.02. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Tetra Tech had a net margin of 8.60% and a return on equity of 22.32%. Tetra Tech’s revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. Tetra Tech has set its Q4 2026 guidance at 0.450-0.480 EPS and its FY 2026 guidance at 1.560-1.590 EPS. As a group, equities analysts expect that Tetra Tech, Inc. will post 1.58 earnings per share for the current fiscal year.
Tetra Tech Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Thursday, August 27th. Stockholders of record on Thursday, August 13th were paid a $0.072 dividend. This represents a $0.29 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Thursday, August 13th. Tetra Tech’s dividend payout ratio (DPR) is 17.47%.
About Tetra Tech (Free Report)
Tetra Tech, Inc is a leading provider of consulting and engineering services with a focus on water, environment, infrastructure, resource management and energy sectors. Headquartered in Pasadena, California, the company delivers end-to-end solutions that encompass planning, design, engineering, program management and construction management. Tetra Tech’s multidisciplinary teams integrate science, technology and advisory services to address complex challenges in areas such as water resources, environmental remediation, sustainable infrastructure and renewable energy.
The company’s core offerings include environmental assessments and cleanup, water treatment and reuse, coastal and marine engineering, climate resilience planning, and engineering design for transportation and built environments.
Featured Stories Five stocks we like better than Tetra Tech Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Want to see what other hedge funds are holding TTEK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tetra Tech, Inc. (NASDAQ:TTEK – Free Report).
Receive News & Ratings for Tetra Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetra Tech and related companies with MarketBeat.com's FREE daily email newsletter.
When a developer needs to make sense of a chaotic mountain of telemetry data, they call on Elastic (ESTC -3.69%). The company provides an essential search-driven platform that powers observability, security, and enterprise search workflows, essentially acting as the digital librarian for modern infrastructure. With the stock trading around $88.42 as of Sept. 8, 2026, and having climbed roughly 17% year-to-date, Elastic has shifted its focus from burning cash for growth to building a profitable, AI-integrated software engine.
Our proprietary Hidden Gems scoring system assigns Elastic an overall Superscore of 80 out of 100, placing it in the Strong category. The Superscore is an AI-powered score that evaluates a company's overall strength by combining financial performance, product market position, technological capabilities, leadership quality, and relative valuation. It represents the unification of all our scores into a single score for public companies, with five rating bands: Exceptional (90-100), Strong (75-89), Above Average (60-74), Average (40-59), and Cautious (0-39). This 80 places the company in the Top ~10% of every company we score. This analysis serves as one data-driven signal to guide your research, pairing the core strengths against the persistent risks to help you weigh the investment case for yourself.
Why Elastic Has an 80 SuperscoreStrong profitability pivot: The company successfully transitioned to GAAP profitability in fiscal 2026, reporting $368 million in net income and demonstrating that its platform can generate significant cash as it scales.AI product momentum: Rapid integration of generative AI tools like 'Search AI' and agentic workflows has deepened its utility, keeping enterprise customers locked into its ecosystem.Operational scale gains: Expanding gross margins to 76% in fiscal 2026 proves that the company is effectively managing the infrastructure costs of its cloud-first, consumption-based subscription model.Market relevance: Its status as a leader in observability and security keeps the platform essential to large enterprises, with over 1,720 customers now paying more than $100k in annual recurring revenue.Why Is Elastic's Superscore Not Higher?Stretched valuation multiples: An EV-to-EBITDA ratio of 502x prices in massive growth, leaving little room for error if expansion slows or if guidance slips.Intense competitive environment: The company competes for market share against well-funded hyperscalers and specialized rivals, preventing it from establishing an unassailable data moat.Normalization of growth: While healthy, the current mid-teen revenue growth represents a maturation phase compared to the hyper-growth periods of the company's earlier history.AI execution risk: Much of its AI-driven revenue is tied to upselling within its existing base, so it still faces the challenge of capturing entirely new segments to maintain its trajectory.Elastic's high capital efficiency -- ranking in the Top ~1% -- means it generates substantial profits relative to its small base of tangible assets. This allows the business to turn each point of revenue growth into outsize returns, a factor that helps justify the current premium investors pay for the stock.
ScoreScore (out of 100)RankSupporting Data PointProduct 1Y87Top ~8%Strong AI innovation like 'Agent Builder' is driving high-value enterprise adoption.Product 5Y71Top ~29%Consistent 23% revenue CAGR from 2022 to 2026 shows successful cloud-native transformation.Financial 1Y84Top ~8%Fiscal 2026 saw a pivotal shift to profitability with $368 million in net income.Financial 5Y75Top ~16%Disciplined cost management reduced the debt-to-equity ratio from 1.43 in 2022 to 0.46 in 2026.Leaders63Bottom ~40%Management provides granular visibility into key SaaS metrics like cRPO and cloud expansion.AI43Top ~20%The company is effectively embedding AI into its core tools but lacks a proprietary data moat.Valuation Risk70Top ~20%The stock trades at a trailing P/E of 27.83, reflecting investor expectations for future growth.Is Elastic Right For Your Portfolio?This stock warrants a closer look if...
You are looking for the best small-cap tech stocks that have successfully matured into profitable, cloud-native platforms.You believe that AI-driven search and observability will remain critical infrastructure for the modern enterprise.You may want to keep researching before buying if...
You are concerned about valuation risk given the high EV-to-EBITDA ratio.You are uncomfortable with the intense competition from cloud giants that could limit long-term pricing power.The Superscore provides a data-driven signal to help organize your research, but it is not a buy recommendation. Please weigh these points against your own risk tolerance and financial objectives before making any investment decisions.
Image source: The Motley Fool.
My Five-year prediction for Elastic stockElastic posted robust Q1 2027 results at the end of August, and the stock rose 48% last month. It's not the only provider of enterprise search services, but most of its rivals are open-source software packages managed by global communities. It's a promising position in the AI boom, as Elastic's tools can help data-rich companies organize and clean up large quantities of messy data before feeding it into proprietary AI and machine learning systems.
That said, I'm looking at a turnaround story in progress. Elastic's revenues have grown consistently in recent years, but I can't say the same for its cash flows and EBITDA. An EV-to-EBITDA ratio above 500 results from close-to-breakeven profits.
On the upside, Elastic is no longer just a search box for websites. Its vector database and Search AI platform have turned it into a context layer for the generative AI era, helping enterprises retrieve and ground data in real time as they rush to build proprietary AI agents.
Over the next five years, I expect Elastic to complete its transition from a high-growth disruptor to a cornerstone of the enterprise software stack. If it can sustain mid-teens revenue growth while pushing non-GAAP operating margins toward 20%, the company could top $3 billion in annual revenue by 2031. Paired with a stable price-to-sales ratio over the same period, Elastic's stock might double by 2031. Just don't expect a smooth ride.
The Hidden Gems Superscore reflects The Motley Fool's proprietary AI-driven evaluation of a company across product, financial, leadership, and valuation pillars as of the article date and may change over time. Performance figures are point-in-time. Past performance does not guarantee future results.
Key Takeaways ABM shares rose 6.4% in three months compared with the industry's 5.6% growth.Technical Solutions revenues jumped 27.2% in Q2 fiscal 2026, driven by data centers, storage & acquisitions.ABM returned cash via dividends and buybacks, while Heathrow ramp-up costs and weather pressured margins. Shares of ABM (ABM - Free Report) have had a decent run over the past three months. The stock has gained 6.4% compared with the industry’s 5.6% growth. The Zacks S&P 500 Composite rose 3.5% during that period.
Image Source: Zacks Investment Research
ABM has a Growth Score of B. This style score condenses key financial metrics to reflect a fair sense of the quality and sustainability of its growth.
The company’s third-quarter fiscal 2026 earnings are expected to increase 23.2% year over year. Its fiscal 2026 and 2027 earnings are projected to rise 15.4% and 9.3%, respectively. Revenues are anticipated to grow 5.3% in fiscal 2026 and 3% in fiscal 2027.
Factors That Bode Well for ABM’s SuccessSegmental Performance Drives Growth: ABM maintains healthy top-line momentum, supported by broad-based segment growth and steady recurring business. Demand remains favorable across energy infrastructure, semiconductors and airport modernization. In the second quarter of fiscal 2026, Technical Solutions revenues jumped 27.2% year over year, driven by data centers, battery energy storage systems and recent acquisitions. Aviation revenues rose 19.5%, supported by healthy travel demand and new wins, including London Heathrow. Manufacturing & Distribution revenues increased 16.5%, aided by client expansions and the WGNSTAR acquisition, while Education revenues grew 1.9% to $232.2 million on price escalations.
Consistent Dividend & Share Buybacks: ABM has maintained a consistent record of shareholder returns through dividends and share repurchases. The company paid dividends of $57.5 million, $56.5 million and $65.6 million in fiscal 2023, 2024 and 2025, respectively, while repurchasing shares worth $138.1 million, $56.1 million and $122.2 million over the same periods. This trend continued in the first half of fiscal 2026, when ABM paid $34.2 million in dividends and repurchased $94.7 million of shares. The sustained pace of capital returns underscores management’s commitment to enhancing long-term shareholder value.
Robust Liquidity Supports Financial Flexibility: ABM’s liquidity position remains healthy, with a current ratio of 1.46 at the end of the second quarter of fiscal 2026, above the industry average of 1.13. The ratio, comfortably above one, indicates sufficient near-term assets to cover short-term obligations and supports financial flexibility.
Watch Out for These Risks to ABM StockStiff Rivalry: Meanwhile, ABM operates in a highly competitive facilities management market, where aggressive bidding can constrain pricing power and margin expansion as labor and operating costs rise. Competition is intensifying around technology and service capabilities, requiring continued investment to protect market share. These dynamics can pressure profitability even as ABM pursues growth opportunities.
Rising Costs Weighing on Margins: Transportation, security and administrative disruptions, ramp-up costs associated with recent contract wins such as Heathrow Airport, an unfavorable contract mix and higher sales investments are weighing on ABM’s profitability. Weather-related expenses are also affecting Aviation margins. Together, these factors pose near-term margin risks despite continued underlying business growth.
ABM has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stocks to ConsiderA couple of better-ranked stocks in the broader Business Services sector are Bright Horizons Family Solutions Inc. (BFAM - Free Report) and CBIZ, Inc. (CBZ - Free Report) .
Bright Horizons Family Solutions carries a Zacks Rank #2 (Buy) at present. It has a long-term earnings growth expectation of 13.9%.
BFAM delivered a trailing four-quarter earnings surprise of 7.6%, on average.
CBIZ also holds a Zacks Rank of 2 at present. It has a long-term earnings growth expectation of 11.6%.
CBZ beat earnings estimates in three of the last four quarters and missed once, with an average earnings surprise of 8.9%.
For the quarter ended July 2026, ABM Industries (ABM - Free Report) reported revenue of $2.32 billion, up 4.2% over the same period last year. EPS came in at $1.04, compared to $0.82 in the year-ago quarter.
The reported revenue represents a surprise of +0.71% over the Zacks Consensus Estimate of $2.3 billion. With the consensus EPS estimate being $1.01, the EPS surprise was +2.97%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how ABM Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- Business & Industry: $1.01 billion versus $1.03 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.6% change.Revenues- Aviation: $328.1 million versus the two-analyst average estimate of $308.36 million. The reported number represents a year-over-year change of +12.4%.Revenues- Education: $235.8 million versus the two-analyst average estimate of $235.05 million. The reported number represents a year-over-year change of +0.3%.Revenues- Manufacturing & Distribution: $481 million compared to the $438.43 million average estimate based on two analysts. The reported number represents a change of +17.6% year over year.Revenues- Technical Solutions: $259.9 million compared to the $279.91 million average estimate based on two analysts. The reported number represents a change of +4.2% year over year.Operating profit- Business & Industry: $75 million versus $84.91 million estimated by two analysts on average.Operating profit- Aviation: $18.4 million versus $17.95 million estimated by two analysts on average.Operating profit- Manufacturing & Distribution: $40.5 million versus the two-analyst average estimate of $40.89 million.Operating profit- Technical Solutions: $21.5 million versus the two-analyst average estimate of $19.66 million.Operating profit- Education: $23 million versus the two-analyst average estimate of $19.39 million.View all Key Company Metrics for ABM Industries here>>>
Shares of ABM Industries have returned -1.8% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
U.S. stocks traded lower midway through trading, with the S&P 500 falling around 0.4% on Tuesday.
The Dow traded down 1.06% to 52,849.66 while the NASDAQ dipped 0.12% to 26,476.11. The S&P 500 also fell, dropping, 0.36% to 7,690.48.
Leading and Lagging Sectors
Energy shares jumped by 1.6% on Tuesday.
In trading on Tuesday, health care stocks fell by 2%.
Top Headline
ABM Industries Inc (NYSE:ABM) posted better-than-expected earnings for the third quarter on Tuesday.
The company posted adjusted earnings of $1.04 per share, beating market estimates of $1.01 per share. The company’s sales came in at $2.317 billion, versus expectations of $2.310 billion.
Equities Trading UP
PDS Biotechnology Corp (NASDAQ:PDSB) shares shot up 65% to $0.36 after the company announced it raised up to $22.55 million in equity funding in a Private Investment in Public Equity transaction. Shares of Roivant Sciences Ltd (NASDAQ:ROIV) got a boost, surging 17% to $40.91 after the company shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Pharvaris NV (NASDAQ:PHVS) shares were also up, gaining 17% to $41.30 after the company announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release tablet for the prevention of HAE attacks. Trending
Equities Trading DOWN
Dyne Therapeutics, Inc (NASDAQ:DYN) shares dropped 23% to $18.76. Dyne Therapeutics will present preclinical data for multiple development candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting. Shares of Novartis AG (NYSE:NVS) were down 13% to $139.95 after the company disclosed that the pelacarsen phase III Lp(a) HORIZON trial did not meet its primary endpoint. Lexaria Bioscience Corp (NASDAQ:LEXX) was down, falling 35% to $9.22 after the company announced a warrant inducement repricing of 453,969 warrants to $12.92 per share from the original prices of $17.85 to $45.90. Commodities
In commodity news, oil traded up 1.5% to $92.88 while gold traded down 0.8% at $4,443.00.
Silver traded up 0.1% to $66.795 on Tuesday, while copper rose 2.5% to $6.8525.
Euro zone
European shares were mixed today. The eurozone’s STOXX 600 rose 0.01%, while Spain’s IBEX 35 Index fell 0.24%, London’s FTSE 100 rose 0.21%, Germany’s DAX slipped 0.12%, while France’s CAC 40 gained 0.05%.
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan’s Nikkei 225 dipping 1.70%, Hong Kong’s Hang Seng index falling 0.38%, China’s Shanghai Composite gaining 0.20% and India’s BSE Sensex dipping 0.73%.
Economics
The Manheim Used Vehicle Value Index declined 0.9% month-over-month in August, recording a second straight monthly decline. The US NFIB Small Business Optimism Index declined to 98.7 in August from 99.8 in the previous month and also missing market estimates of 99.3. Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
ABM Industries Incorporated (NYSE:ABM – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $50.42 and last traded at $50.6430, with a volume of 454932 shares. The stock had previously closed at $47.05.
The business services provider reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. ABM Industries had a return on equity of 11.84% and a net margin of 1.75%.The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.32 billion. During the same quarter last year, the company earned $0.82 earnings per share. The company’s quarterly revenue was up 4.2% on a year-over-year basis. ABM Industries has set its FY 2026 guidance at 3.950-4.100 EPS.
ABM Industries Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Thursday, October 1st will be paid a dividend of $0.29 per share. The ex-dividend date is Thursday, October 1st. This represents a $1.16 dividend on an annualized basis and a yield of 2.3%. ABM Industries’s dividend payout ratio is presently 44.62%.
Trending Headlines about ABM Industries Here are the key news stories impacting ABM Industries this week: Positive Sentiment: Quarterly earnings beat estimates: Adjusted EPS rose 27% year over year to $1.04, exceeding the $1.01 consensus estimate. Revenue increased 4.2% to a record approximately $2.3 billion, in line with expectations. ABM Industries Q3 Earnings and Revenues Beat Estimates Positive Sentiment: Profitability and cash generation improved: Net income increased 19% to $49.7 million, adjusted EBITDA rose 11% to $139.6 million, and quarterly free cash flow reached $128.4 million. Nine-month operating and free cash flow also improved substantially year over year. ABM Reports Fiscal Third Quarter 2026 Results Positive Sentiment: Fiscal 2026 outlook raised: ABM now expects adjusted EPS of $3.95 to $4.10, with the midpoint above the $3.98 analyst consensus. The company also increased its operating cash flow and free cash flow expectations, signaling confidence in execution. Positive Sentiment: Dividend maintained: ABM declared a quarterly dividend of $0.29 per share, equivalent to $1.16 annually and a yield of approximately 2.3%. The dividend is payable November 2 to shareholders of record October 1. Neutral Sentiment: Revenue growth consisted of 2.1% organic growth and 2.1% acquisition-related growth, indicating acquisitions remain an important contributor to expansion. Negative Sentiment: Analysts’ average price target was reported at $47, below the stock’s recent trading level, potentially limiting near-term upside. Margin pressure and competition also remain risks despite the stronger quarter. Analysts Set New Price Targets Several equities research analysts have recently commented on ABM shares. Robert W. Baird lifted their price objective on shares of ABM Industries from $45.00 to $48.00 and gave the stock a “neutral” rating in a research note on Monday, June 8th. Weiss Ratings raised ABM Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $47.00.
Read Our Latest Research Report on ABM
Insider Buying and Selling at ABM Industries In related news, CEO Scott Salmirs sold 50,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $46.34, for a total transaction of $2,317,000.00. Following the completion of the transaction, the chief executive officer owned 395,285 shares of the company’s stock, valued at $18,317,506.90. This trade represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.90% of the stock is owned by insiders.
Institutional Investors Weigh In On ABM Industries Several hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. purchased a new position in ABM Industries in the 1st quarter valued at about $12,739,000. First Eagle Investment Management LLC purchased a new stake in ABM Industries during the 4th quarter worth approximately $7,623,000. Quantinno Capital Management LP increased its stake in ABM Industries by 86.3% during the 1st quarter. Quantinno Capital Management LP now owns 54,790 shares of the business services provider’s stock worth $2,111,000 after buying an additional 25,388 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of ABM Industries during the first quarter valued at approximately $1,002,000. Finally, BlackRock Inc. acquired a new position in shares of ABM Industries during the second quarter valued at approximately $410,948,000. 91.62% of the stock is owned by hedge funds and other institutional investors.
ABM Industries Stock Performance The firm has a market cap of $2.97 billion, a PE ratio of 19.51, a P/E/G ratio of 1.23 and a beta of 0.68. The firm has a 50-day moving average price of $47.12 and a two-hundred day moving average price of $43.17. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 1.04.
ABM Industries Company Profile (Get Free Report)
ABM Industries Incorporated is a leading provider of integrated facility services, offering a comprehensive suite of solutions designed to support the operation, maintenance and enhancement of commercial properties. The company’s core services include janitorial and custodial maintenance, HVAC and mechanical systems support, electrical and lighting solutions, and energy optimization. Additional offerings span parking management, security services, landscaping, and specialized support such as technical solutions and sustainability consulting.
Serving a diverse range of markets, ABM caters to clients in commercial real estate, aviation, healthcare, manufacturing, education, government entities, and technology campuses.
Featured Articles Five stocks we like better than ABM Industries Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For Receive News & Ratings for ABM Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABM Industries and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of ACI Worldwide (ACIW - Free Report) have gained 0.2% over the past four weeks to close the last trading session at $52.95, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $67.33 indicates a potential upside of 27.2%.
The average comprises three short-term price targets ranging from a low of $66.00 to a high of $70.00, with a standard deviation of $2.31. While the lowest estimate indicates an increase of 24.7% from the current price level, the most optimistic estimate points to a 32.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for ACIW, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You Should Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Why ACIW Could Witness a Solid UpsideAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The Zacks Consensus Estimate for the current year has increased 4.5% over the past month, as one estimate has gone higher compared to no negative revision.
Moreover, ACIW currently has a Zacks Rank #1 (Strong Buy), which means it is in the top 5% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much ACIW could gain, the direction of price movement it implies does appear to be a good guide.
LOS ANGELES, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Papa John's International, Inc. (“Papa John’s” or “the Company”) (NASDAQ: PZZA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of PZZA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: August 7, 2025 to August 5, 2026
DEADLINE: November 2, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The transformation plan developed by Papa John’s was not achieving results in the expected timeframe. The Company failed to prevent further erosion in market share. The Company was forced to sharply increase promotional efforts to preserve market share. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Papa John’s, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Papa John's International, Inc. (NASDAQ: PZZA) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Papa John's securities between August 7, 2025 and August 5, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/papa-johns-international-inc-pzza-class_action_lawsuit.
Papa John's Case Details
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
(1) Papa Johns’ transformation efforts were taking longer than expected;
(2) the Company was unable to prevent further losses in market share;
(3) Papa Johns would require a significant shift in strategy, including a sharp increase in promotional efforts, to address the Company’s declining competitive position; and
(4) as a result, Defendants’ positive statements concerning the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
What's Next for Papa John's Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/papa-johns-international-inc-pzza-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Papa John's you have until November 2, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Papa John's Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Papa John's Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
New York, New York--(Newsfile Corp. - September 8, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Papa John's International, Inc. (NASDAQ: PZZA) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Papa John's securities between August 7, 2025 and August 5, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/cases/papa-johns-international-inc-pzza-class_action_lawsuit.
Papa John's Case Details
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that:
Papa Johns' transformation efforts were taking longer than expected; the Company was unable to prevent further losses in market share; Papa Johns would require a significant shift in strategy, including a sharp increase in promotional efforts, to address the Company's declining competitive position; and as a result, Defendants' positive statements concerning the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.What's Next for Papa John's Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/cases/papa-johns-international-inc-pzza-class_action_lawsuit, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Papa John's you have until November 2, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Papa John's Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Papa John's Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312916
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Papa John's To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Papa Johns between August 7, 2025 and August 5, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - September 8, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Papa John's International Inc. ("Papa Johns" or the "Company") (NASDAQ: PZZA) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of Papa Johns' transformation; notably, that it was "taking longer than expected," and ultimately was unable to prevent further market share losses. Papa Johns ultimately required a significant shift in strategy toward a sharp increase in promotional efforts to abate the Company's declining competitive position.
On August 6, 2026, Papa Johns announced an 8.3% decrease in North American comparable sales, the suspension of its dividend, and a sharp reduction in its 2026 outlook from a 3% decline in North American comparable sales at the midpoint to a 7% annual decline. The Company attributed its strategic shift and guidance reset on the soft consumer trends and the execution of Papa Johns' own turnaround efforts, admitting they were unable to "meet the consumer as much as [they] should have," and the rebuilt innovation pipeline was "not bringing in as many new customers" as had been expected.
On this news, the price of Papa Johns' common stock declined dramatically. From a closing market price of $29.75 per share on August 5, 2026, Papa Johns' stock price fell to $24.64 per share on August 6, 2026, a decline of about 17.18% in the span of just a single day.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Papa Johns' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about Papa John's International Inc. class action, go to www.faruqilaw.com/PZZA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Papa Johns Securities Class Action Lawsuit:
What is the Papa Johns securities fraud lawsuit about?
The lawsuit alleges Papa Johns misled investors about its transformation strategy, including delays in its turnaround, continued market share losses, and the need for increased promotions to address its declining competitive position.
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Papa John's International (NASDAQ: PZZA) securities between August 7, 2025 and August 5, 2026 may be eligible if they suffered losses.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by November 2, 2026. Investors may participate without serving as lead plaintiff.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Papa Johns securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313371
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Papa John's International, Inc. (“Papa John's” or the “Company”) (NASDAQ: PZZA) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PAPA JOHN'S INTERNATIONAL, INC. (PZZA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About?On August 6, 2026, Papa John's issued its.
WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Papa John’s International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.
SO WHAT: If you purchased Papa Johns common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or concealed material adverse facts concerning the true state of Papa Johns’ transformation; notably, that it was “taking longer than expected,” and ultimately was unable to prevent further market share losses. Papa Johns ultimately required a significant shift in strategy toward a sharp increase in promotional efforts to abate Papa Johns’ declining competitive position. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Papa John's International, Inc. (NASDAQ: PZZA) between August 7, 2025 and August 5, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.
SO WHAT: If you purchased Papa Johns common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or concealed material adverse facts concerning the true state of Papa Johns' transformation; notably, that it was "taking longer than expected," and ultimately was unable to prevent further market share losses. Papa Johns ultimately required a significant shift in strategy toward a sharp increase in promotional efforts to abate Papa Johns' declining competitive position. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Papa Johns class action, go to https://rosenlegal.com/cases/papa-johns-international-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313576
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Whirlpool (WHR - Free Report) closed the most recent trading day at $37.61, moving -4.3% from the previous trading session. This move lagged the S&P 500's daily loss of 0.58%. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.
Coming into today, shares of the maker of Maytag, KitchenAid and other appliances had lost 6.81% in the past month. In that same time, the Consumer Discretionary sector lost 2.32%, while the S&P 500 lost 0.36%.
The investment community will be paying close attention to the earnings performance of Whirlpool in its upcoming release. The company is predicted to post an EPS of $1.01, indicating a 51.67% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.99 billion, down 1.07% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.25 per share and a revenue of $14.92 billion, representing changes of -63.88% and -3.92%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Whirlpool. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Whirlpool currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Whirlpool currently has a Forward P/E ratio of 17.47. This indicates no noticeable deviation in contrast to its industry's Forward P/E of 17.47.
It's also important to note that WHR currently trades at a PEG ratio of 17.47. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Household Appliances industry held an average PEG ratio of 8.95.
The Household Appliances industry is part of the Consumer Discretionary sector. With its current Zacks Industry Rank of 102, this industry ranks in the top 42% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Hanover Insurance Group (THG - Free Report) , which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Hanover Insurance Group currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for THG that show why this insurance company shows promise as a solid momentum pick.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For THG, shares are up 0.31% over the past week while the Zacks Insurance - Property and Casualty industry is up 0.15% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 1.16% compares favorably with the industry's 0.76% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Shares of Hanover Insurance Group have increased 15.19% over the past quarter, and have gained 28.51% in the last year. In comparison, the S&P 500 has only moved 4.72% and 20.24%, respectively.
Investors should also take note of THG's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now THG is averaging 256,932 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with THG.
Over the past two months, 5 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost THG's consensus estimate, increasing from $18.38 to $20.17 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been no downward revisions in the same time period.
Bottom LineTaking into account all of these elements, it should come as no surprise that THG is a #1 (Strong Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Hanover Insurance Group on your short list.
Joint research team modeled a 12,635-atom protein, the largest-known to be simulated using quantum computers.
Breakthrough was achieved through quantum and classical methods working together, expanding quantum-centric supercomputing's potential in life sciences research.
, /PRNewswire/ -- A multidisciplinary team from Cleveland Clinic, RIKEN and IBM (NYSE: IBM) has been named as a finalist for the 2026 Association for Computing Machinery (ACM) Gordon Bell Prize for simulating the largest biologically meaningful molecules ever modeled with quantum computers, reaching a scale of 12,635 atoms. To achieve these results, the team united the strengths of quantum and classical computing methods in a framework known as quantum-centric supercomputing.
The ACM Gordon Bell Prize recognizes outstanding achievement in high-performance computing and is one of the field's most prestigious honors. The 2026 winner will be announced at the International Conference for High-Performance Computing, Networking, Storage, and Analysis (SC26), taking place Nov. 15–20, 2026 in Chicago.
The origins of the project are rooted in the team's investigation into how computation in drug discovery can be improved. Doing so rests on two fundamental challenges: first, modeling the movement of atoms as biological processes unfold; and second, accurately computing their energies. Particularly the second challenge is well-suited for quantum computers, which operate by the laws of quantum mechanics.
In the work, initially published in May 2026, the team calculated the electronic structure of two large protein complexes using the IBM Quantum Heron processors running within the IBM quantum computers at Cleveland Clinic in the United States and RIKEN in Japan. The calculations were executed alongside two of the world's most powerful supercomputers, Fugaku at RIKEN and Miyabi-G, which is operated by the University of Tokyo and University of Tsukuba. The quantum computers used up to 94 qubits to run nearly 6,000 quantum operations within certain parts of the problem, which was essential to the computation's accuracy and success. Fugaku and Miyabi-G were used to reassemble the results and allow the team to gain a complete representation of each molecule.
The results reflect the team's innovative approach alongside the rapid maturation of quantum computing. Using the sample-based quantum diagonalization by IBM and RIKEN (featured on the cover of Science Advances) along with embedded wavefunction methods adapted by Cleveland Clinic to the question at hand, the team was able to report the first-known simulation of a 303-atom protein achieved with quantum computers. Less than a year later, the team first scaled their method roughly 40 times while also achieving 210 times improvement in accuracy. In updated results recently published in September, the team advanced the work even further. Most notably, they were able to further improve the accuracy of their computations of the binding energies of the molecular system, which reflect how tightly the molecules are bound together and can predict how they could interact with other systems.
In addition, the team validated the workflow on a third supercomputer, JHPC-quantum GPU supercomputer "ROQUO," RIKEN's newest system in a way that eliminated the need for complex manual operations and data transfers – pointing toward faster, more accessible research. By orchestrating CPUs, GPUs, and QPUs together, the team minimized the need for manual transfers and further reduced errors — an early demonstration of how classical and quantum computing can work in concert on complex scientific problems.
Taken together with the earlier results, these updates reflect continued progress on both the accuracy of computed binding energies and the time-to-solution enabled by the automated workflow.
The quantum-classical techniques developed by the team continues to reduce the computational overhead required to directly represent the chemistry of molecular systems with accuracy and is pushing the frontiers of what is possible with quantum-centric supercomputing in the field. The work has demonstrated a path to further increase the accuracy of how molecular system can be calculated and is a step towards helping researchers better predict how medicines may interact with protein targets.
The research team includes Kenneth Merz Jr, Akhil Shajan, Danil Kaliakin, Fangchun Liang of Cleveland Clinic, Yuichi Otsuka, Tomonori Shirakawa, Lukas Broers, Han Xu, Miwako Tsuji, Mitsuhisa Sato, Seiji Yunoki of RIKEN Center for Computational Science, and Ryo Wakizaka, Yukio Kawashima, Jun Doi, Hitomi Takahashi, Toshinari Itoko, Hiroshi Horii, Thaddeus Pellegrini, Javier Robledo Moreno, Kevin J. Sung, Ella Fejer, Robert Walkup, Seetharami Seelam, Mario Motta of IBM.
To read the full study, visit: https://arxiv.org/abs/2605.01138
Research Support
This research is supported by NEDO (New Energy and Industrial Technology Development Organization), an organization under the jurisdiction of Japan's Ministry of Economy, Trade and Industry (METI)'s "Research and Development of Quantum-Supercomputers Hybrid Platform for Exploration of Uncharted Computable Capabilities" (Project Leader: Mitsuhisa Sato) as part of the "Project for Research and Development of Enhanced Infrastructures for Post 5G Information and Communications Systems (JPNP20017)."
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic's 83,000 employees worldwide are more than 6,600 salaried physicians and researchers, and 21,900 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,725-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 300 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2025, there were 15.9 million outpatient encounters, 343,000 hospital admissions and observations, and 336,000 surgeries and procedures throughout Cleveland Clinic's health system. Visit us at clevelandclinic.org. Follow us at x.com/CleClinicNews. News and resources are available at newsroom.clevelandclinic.org.
About RIKEN
RIKEN is Japan's leading national comprehensive research institute in the natural sciences, conducting research across a broad range of fields including physics, engineering, chemistry, mathematical and information sciences, computational science, biology, and medical science. The RIKEN Center for Computational Science (R-CCS) operates the world-class supercomputer Fugaku, providing computing resources to a wide range of users in universities, research institutions, and industry, and carries out research and development under the banner of "The Science of computing, by computing, and for computing", contributing to the advancement of computational science and computer science.
For more information, visit https://www.riken.jp/en/.
About IBM
IBM is a leading global hybrid cloud and AI, and business services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of governments and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM's legendary commitment to trust, transparency, responsibility, inclusivity and service.
For more information, visit https://research.ibm.com.
R-CCS, Computational Science Promotion Division Outreach Group
[email protected]
Danielle Cerasani Estevez
IBM Research Communications
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/cleveland-clinic-riken-and-ibm-team-advance-to-finals-for-2026-acm-gordon-bell-prize-302872821.html
WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD's human pancreatic beta cell models to Revvity's Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including.
- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against placebo in clinically meaningful exploratory endpoints including sleep apnea and otitis media events
Stabilization of sleep apnea measures: The mean total Apnea-Hypopnea Index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo group; in children younger than 8 years of age, the mean total AHI was unchanged for the oral infigratinib group, versus a 63.2% increase in the placebo groupReduction in rate of ear infections: The estimated annualized rate of otitis media events was 38% lower in the oral infigratinib group compared to the placebo group; in children younger than 8 years of age, the annualized rate of otitis media events was 47% lower in the oral infigratinib group compared to the placebo group
- In children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained improvements in growth (CFBL in height Z-score of +0.92 SD at Year 3) and body proportionality (CFBL in upper-to-lower body segment ratio of -0.15 at Year 3), with a well-tolerated safety profile and no new safety signals
- These findings build on the previously reported PROPEL 3 primary and secondary endpoint results published in NEJM, in which oral infigratinib demonstrated a +2.10 cm/year improvement in AHV versus placebo (p<0.0001) and a statistically significant improvement in body proportionality within 52 weeks in children younger than 8 years of age
- BridgeBio submitted an NDA to the FDA for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027
PALO ALTO, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today presented new exploratory analyses from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, showing directionally favorable trends beyond growth across medical complications associated with achondroplasia, including sleep apnea, otitis media, and body composition. These data were presented at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026 in Marseille, France, in a late-breaking oral presentation by Julie Hoover-Fong, M.D., Ph.D. of Johns Hopkins University, U.S.
"In the past, achondroplasia research has focused largely on measuring growth because height can be readily determined. But families have consistently emphasized that their priorities extend well beyond the growth chart," said Melita Irving, M.D. of Guy's and St Thomas' NHS Foundation Trust, London, UK. "Growth is only one part of the picture of this medically complicated condition in which children experience disrupted sleep, recurring ear infections, or other health challenges associated with achondroplasia. What I find especially encouraging here is not only the consistent benefit observed across each measure, but that the longer-term data from the PROPEL program show improvements in growth and body proportionality sustained through three years of treatment, and a safety profile that remained favorable with no new safety signals identified. Taken together, these findings suggest there is potential to address a broader range of outcomes that may meaningfully affect a child's health and daily life over time."
The new exploratory results from PROPEL 3 shared at ESPE 2026 include:
Stabilization of sleep apnea measures: The mean total apnea-hypopnea index (AHI) at 52 weeks remained consistent with the baseline mean in the oral infigratinib group, with a 10.4% increase, versus a 49.2% increase in the placebo groupIn children younger than 8 years of age, the mean total AHI at 52 weeks was unchanged for the oral infigratinib group, versus a 63.2% increase for the placebo group Reduction in rate of ear infections: The estimated annualized rate of otitis media, a recurrent complication in children with achondroplasia that can affect hearing and speech development, was 38% lower in the oral infigratinib group compared to the placebo group, and in children younger than 8 years of age, 47% lower in the oral infigratinib group compared to the placebo groupImpact on body composition: Mean change from baseline in body mass index was smaller in the oral infigratinib group compared to placebo (0.50 versus 0.93 kg/m2), with a greater increase in lean body mass (1.77 versus 1.58 kg) and smaller increases in body fat mass (0.95 versus 1.12 kg) and visceral fat volume (1.55 versus 18.42 mL) compared to placebo
In addition to the late-breaking oral presentation at the Annual ESPE Meeting 2026, BridgeBio shared a poster, Longer-Term Efficacy and Safety Results of Infigratinib in Children with Achondroplasia, presented by Dr. Irving. These findings showed that in children treated for up to three years in the PROPEL program, oral infigratinib demonstrated sustained improvements in growth, with a change from baseline in height Z-score relative to the achondroplasia population of +0.92 SD at Year 3. Additionally, oral infigratinib demonstrated sustained improvements in proportionality, with a change from baseline in upper-to-lower body segment ratio of -0.15 at Year 3. Results showed that oral infigratinib continued to be well-tolerated, with no new safety signals identified.
BridgeBio also shared one poster focused on PROPEL Infant & Toddler (I&T), an ongoing Phase 2/2b study in children under 3 years old with achondroplasia and one eposter focused on qualitative research on the impacts of hypochondroplasia.
PROPEL 3 demonstrated best-in-class improvements in annualized height velocity (AHV) and, for the first time in a Phase 3 achondroplasia study, statistically significant improvements in body proportionality and arm span, supporting its potential as the first oral targeted therapeutic option that directly impacts FGFR3. The topline results can be found here. These data were published as an original research article in the New England Journal of Medicine (NEJM) and simultaneously presented at the International Congress of Children’s Bone Health (ICCBH) 2026 in a late-breaking oral presentation. The results can be found here.
BridgeBio believes oral infigratinib is positioned to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia. The Company submitted an NDA to the FDA for oral infigratinib in achondroplasia and anticipates a U.S. launch in mid-2027. The Company intends to submit a Marketing Authorization Application (MAA) for achondroplasia to the European Medicines Agency (EMA) in the fourth quarter of 2026.
Oral infigratinib has received Breakthrough Therapy Designation from the U.S. FDA based on the shared results from the PROPEL 2 clinical trial, which meet the FDA’s requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoints. In addition to receipt of Breakthrough Therapy Designation, oral infigratinib has also received Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designation for achondroplasia from the FDA. If oral infigratinib is approved, BridgeBio may qualify for a Priority Review Voucher.
Information about PROPEL I&T trial (NCT07169279) can be found here on clinicaltrials.gov. Information about ACCEL, the Company’s observational lead-in study for oral infigratinib in hypochondroplasia’s Phase 3 study (NCT06410976) can be found here, and information about ACCEL 2/3, BridgeBio’s Phase 2/3 clinical study of oral infigratinib in hypochondroplasia (NCT06873035) can be found here. BridgeBio is committed to exploring the potential of oral infigratinib on wider medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions, which hold significant unmet needs for families.
About Achondroplasia
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the U.S. and European Union (EU), including up to 10,000 children and adolescents with open growth plates. Achondroplasia can be associated with medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis, which may impact overall health and wellbeing. The condition is uniformly caused by an activating variant in FGFR3.
About Oral Infigratinib
Oral infigratinib is an investigational small molecule designed to inhibit FGFR3 signaling and target skeletal dysplasias, including achondroplasia and hypochondroplasia, at their source. Overactivating FGFR3 pathogenic variants drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and the potential for serious health complications. Oral infigratinib improves bone growth by decreasing the overactivity of FGFR3.
About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “hopes,” “intends,” “may,” “plans,” “projects,” “remains,” “seeks,” “should,” “will,” and variations of such words or similar expressions, or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. BridgeBio intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements include statements regarding the potential clinical significance and therapeutic implications of the data regarding oral infigratinib, including the potential for oral infigratinib to provide benefits beyond growth and to meaningfully affect a broader range of medical and functional outcomes associated with achondroplasia; the potential for oral infigratinib to become the first and only approved oral therapy and a potential best-in-class option for children living with achondroplasia; the potential regulatory approval and commercialization of oral infigratinib, including BridgeBio’s anticipated U.S. launch in mid-2027; BridgeBio’s plans to submit a Marketing Authorization Application for oral infigratinib in achondroplasia to the European Medicines Agency in the second half of 2026; BridgeBio’s potential eligibility to receive a Priority Review Voucher if oral infigratinib is approved; and BridgeBio’s plans to continue exploring the potential of oral infigratinib to address broader medical and functional impacts of achondroplasia, hypochondroplasia, and other skeletal dysplasia conditions. Although the Company believes that its plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, the Company can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, initial and ongoing data from the Company’s clinical trials not being indicative of final data; the design, enrollment, conduct, timing and success of ongoing and planned clinical trials; the risk that results from exploratory endpoints, subgroup analyses or other analyses may not be predictive of future clinical outcomes or treatment effects; that observed trends or improvements in medical or functional outcomes may not be replicated in additional analyses or studies or translate into meaningful long-term clinical benefits; that oral infigratinib may not demonstrate benefits beyond growth or achieve the anticipated clinical, regulatory or commercial profile; that the FDA, EMA or other regulatory authorities may not approve oral infigratinib on the anticipated timeline or at all, or may require additional data, studies or other information; that BridgeBio may not launch oral infigratinib in the U.S. in mid-2027 or on the anticipated timeline; that BridgeBio’s planned regulatory submissions, including its planned MAA submission, may be delayed or may not occur as expected; that oral infigratinib may not become the first and only approved oral therapy or a best-in-class option for achondroplasia; that BridgeBio may not qualify for or receive a Priority Review Voucher; and that BridgeBio’s plans to study or develop oral infigratinib for broader medical and functional impacts or additional skeletal dysplasia conditions may change or may not result in successful development or regulatory approval; the impacts of current macroeconomic and geopolitical events, including changing conditions from hostilities in Ukraine and the Middle East, increasing rates of inflation and changing interest rates, on business operations and expectations, as well as those risks set forth in the Risk Factors section of the Company’s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission. Moreover, the Company operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of the Company’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, BridgeBio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
LOS ANGELES, Sept. 8, 2026 /PRNewswire/ -- KB Home (NYSE: KBH) today announced that it will release earnings for its third quarter ended August 31, 2026 after the market closes on Tuesday, September 22, 2026.
In the latest close session, KB Home (KBH - Free Report) was down 3.92% at $50.20. The stock fell short of the S&P 500, which registered a loss of 0.58% for the day. Meanwhile, the Dow experienced a drop of 1.18%, and the technology-dominated Nasdaq saw a decrease of 0.32%.
Prior to today's trading, shares of the homebuilder had lost 7.55% was narrower than the Construction sector's loss of 7.66% and lagged the S&P 500's loss of 0.36%.
The upcoming earnings release of KB Home will be of great interest to investors. The company is expected to report EPS of $0.88, down 45.34% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $1.29 billion, down 20.14% from the prior-year quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $3.3 per share and revenue of $5.09 billion, which would represent changes of -49.39% and -18.37%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for KB Home. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. KB Home is currently a Zacks Rank #3 (Hold).
With respect to valuation, KB Home is currently being traded at a Forward P/E ratio of 15.85. This expresses a premium compared to the average Forward P/E of 13.59 of its industry.
We can also see that KBH currently has a PEG ratio of 2.68. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Building Products - Home Builders industry had an average PEG ratio of 2.68 as trading concluded yesterday.
The Building Products - Home Builders industry is part of the Construction sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Reshoring has become an important theme in U.S. manufacturing. However, it does not simply mean moving an entire overseas factory back home.
Reshoring can also involve replacing imported components or processing with domestic capacity. The distinction changes which industrial stocks are positioned to benefit.
Image source: Getty Images.
Reshoring can happen inside the supply chain According to the 2026 Reshoring Initiative survey, among surveyed contract manufacturers, 69% of reshoring cases involved customers switching component sourcing to the U.S. while assembly was already domestic.
Premium Feature
Moneyball Superscore
68/100
Today's Change
(
1.54
%) $
0.84
Current Price
$
55.37
MP Materials (MP +1.54%) is a good example. The company is expanding rare-earth processing and magnet production in the U.S. The company's new 10X facility in Texas is expected to produce 7,000 metric tons of magnets annually once fully scaled. MP Materials expects to invest more than $1.25 billion in the project. The expansion is part of MP Materials' effort to build an end-to-end U.S. rare-earth magnet supply chain and reduce dependence on foreign production.
Government support also reduces some of the risk around this expansion. The Pentagon has agreed to cover the shortfall if benchmark prices for MP's key rare-earth materials fall below $110 per kilogram. The Pentagon has also guaranteed that 10X will generate at least $140 million of annual EBITDA once the facility reaches full production.
The economics must still work Reshoring can reduce supply chain risks, but U.S. manufacturers still must compete on price. In the 2026 USA Reshoring survey, 94% of contract manufacturers said price was the main reason they lost orders to imports. Among those losing on price, half said the winning import bid was at least 30% lower.
Among original equipment manufacturers (OEMs) reporting impacts from reshoring, 70% cited faster speed to market, 65% better on-time delivery, and 60% logistics savings. However, investors should not assume reshoring interest means a factory-building boom. U.S. manufacturing construction spending fell from $250 billion annualized in September 2024 to about $170 billion in July 2026, down roughly 32%.
Hence, investors should assess whether reshoring is actually translating into more orders and stronger earnings.
Manali Pradhan, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends MP Materials. The Motley Fool has a disclosure policy.
ARES' stock price has jumped by roughly 16.5% since my last strong buy rating. ARES delivered robust double-digit FRE growth (~20%) and record fundraising, with AUM reaching $671B and FPAUM at $410B. The infrastructure segment is driving outsized growth, with FRE up ~30% year-over-year. I expect more upside thanks to the AI and power infrastructure.
MaxLinear, Inc. is rated 'Buy' following a 50%+ dip, with a $105/share price target and 67% upside potential. MXL's Keystone PAM4 DSP, Rushmore, and Annapurna platforms, plus Panther accelerators, are expected to drive substantial growth through 2027-2028. Q2 2026 saw Infrastructure segment revenue up 145% YoY; Q3 guidance implies 27% QoQ growth and ~60% adjusted gross margin.
Key Takeaways Chewy's Q2 revenues are seen rising 6.8% to $3.32B, with EPS up 9.1% to 36 cents.Autoship, customer reactivation, app engagement and healthcare expansion likely supported Q2 sales.Cautious spending, tougher margin comparisons and fuel surcharges may have pressured profitability. Chewy, Inc. (CHWY - Free Report) is scheduled to report second-quarter fiscal 2026 earnings results on Sept. 9, before the opening bell. The key question for investors is whether the online pet retailer can sustain its solid sales momentum and expanding profitability while navigating a dynamic consumer environment and ongoing investments in customer growth, healthcare and other strategic initiatives.
The Zacks Consensus Estimate for second-quarter revenues stands at $3,322 million, indicating a 6.8% increase from the prior-year reported figure. On the earnings front, the consensus estimate has remained stable at 36 cents a share over the past 30 days, implying a 9.1% rise from the year-ago period.
Chewy has an average trailing four-quarter earnings surprise of 0.8%. In the last reported quarter, this Plantation, FL-based company’s bottom line met the Zacks Consensus Estimate.
Image Source: Zacks Investment Research
What the Zacks Model Indicates for CHWY’s Q2 EarningsAs investors prepare for Chewy’s second-quarter results, the question looms regarding an earnings beat or miss. Our proven model does not conclusively predict an earnings beat for Chewy this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that’s not the case here. You can see the complete list of today’s Zacks #1 Rank stocks here.
Chewy has a Zacks Rank #4 (Sell) and an Earnings ESP of -0.61%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Factors Likely to Have Shaped Chewy’s Q2 OutcomeChewy’s second-quarter performance is likely to have benefited from the continued strength of its recurring-revenue model, particularly the Autoship program. Management indicated that Autoship remained a key source of customer engagement and repeat purchasing, helping support revenue visibility even as the broader consumer environment remains cautious. Healthy reactivation trends, lower churn and improved customer relationship management initiatives also appear to have supported the active-customer base. Increased engagement through Chewy’s mobile app and continued market share gains are likely to have provided additional support to sales during the quarter.
The company’s expanding health and wellness ecosystem is also likely to have remained an important growth driver. Management highlighted increasing health and wellness penetration and broader cross-category engagement as factors supporting customer spending. Chewy Vet Care, in particular, has been positioned as both a customer-acquisition and retention engine, with clinic customers showing deeper engagement with the broader Chewy platform. The continued expansion of veterinary services, together with Chewy’s pharmacy and health offerings, may have helped the company capture a larger share of pet-parent spending and strengthen customer loyalty.
We note that sponsored advertising remained an important contributor to margin improvement, while favorable category mix, fulfillment productivity and disciplined operating expenses continued to support operating leverage. The company has also been embedding automation and artificial intelligence across customer service, pharmacy, fulfillment and marketing workflows, with the aim of lowering costs and better serving customers.
However, the second quarter is likely to have been affected by a more cautious consumer backdrop. Chewy entered the period seeing pressure on premiumization and discretionary product attachment. Management also expected a tougher gross-margin comparison because of nonrecurring pricing benefits recorded in the prior-year period, while elevated carrier fuel surcharges are expected to have weighed on profitability.
Chewy Stock Price PerformanceChewy, which competes with Central Garden & Pet Company (CENT - Free Report) and Petco Health and Wellness Company, Inc. (WOOF - Free Report) , has seen its shares jump 15.9% over the past three months compared with the industry’s 6.1% rise. Shares of Central Garden & Pet Company have gained 0.6%, while Petco Health and Wellness Company has fallen 0.8% over the said period.
Image Source: Zacks Investment Research
How Does Chewy’s Valuation Stack Up?Chewy trades at a discount to the broader industry. The stock currently carries a forward 12-month price-to-sales (P/S) multiple of 0.69, well below the industry average of 1.91. It also trades below its 12-month median P/S multiple of 0.79.
Chewy trades at a discount to Central Garden & Pet Company, which carries a forward 12-month P/S multiple of 0.90, but at a premium to Petco Health and Wellness Company, which trades at a multiple of 0.14.
Image Source: Zacks Investment Research
Final Words on ChewyChewy enters its second-quarter earnings release with encouraging business momentum, supported by Autoship strength, improving customer engagement, healthcare expansion, advertising growth and ongoing operating efficiencies. However, cautious consumer spending, softer discretionary demand, tougher margin comparisons and higher delivery-related costs could temper near-term performance. The earnings setup does not provide a favorable signal for a potential beat, warranting added caution despite the stock’s relatively attractive valuation.
Key Takeaways Teradyne's Semiconductor Test sales jumped 128% year over year to $1.12B in Q2 2026. New UltraFLEXplus tools target AI and data-center digital, PCIe Gen6 and high-power test needs. Teradyne expects Q3 revenues of $1.20-$1.30B as AI demand supports UltraFLEXplus adoption. Teradyne (TER - Free Report) is benefiting from accelerating artificial intelligence (AI)-driven semiconductor test demand, particularly across high-performance compute, networking, and advanced memory applications, positioning the company as a formidable player against KLA (KLAC - Free Report) and Cohu (COHU - Free Report) . The company’s growing demand for its UltraFLEXplus system, which is designed to address the complex testing requirements of high-performance processors and networking devices, has been noteworthy. UltraFLEXplus enables customers to reduce test development time, driving higher-efficiency volume production.
Building on this momentum, Teradyne recently launched three new instruments for its UltraFLEXplus semiconductor test platform to address growing AI and data-center computing requirements. The UltraPin5000-EM offers expanded vector memory and faster pattern loading for complex AI devices, while UltraPort-PCIe6 supports PCIe Gen6 testing at 64 Gbps across 32 lanes. The UltraVS64-HP delivers up to 1,280 amps per instrument to test increasingly power-intensive compute devices. Together, the products expand UltraFLEXplus capabilities across advanced digital, high-speed interface and power testing, supporting semiconductor manufacturers from wafer probe through final device validation.
The UltraFLEXplus system has proven to be a key driver in boosting the Semiconductor Test business. In the second quarter of 2026, Teradyne delivered a remarkable 128% year-over-year growth in its Semiconductor Test business, contributing $1.12 billion out of the company’s total $1.3 billion in sales. This segment alone accounted for 84% of total sales.
The growing demand for AI-driven applications, particularly in data centers, is expected to continue driving the adoption of UltraFLEXplus. The strong demand for UltraFLEXplus is likely to support top-line growth, strengthening Teradyne’s competitive position against KLA and Cohu in the semiconductor test market. For the third quarter of 2026, Teradyne expects revenues in the range of $1.20-$1.30 billion.
How Competitors Fare Against TERTeradyne is facing stiff competition from companies such as KLA and Cohu. Both companies are expanding their footprint in the AI space.
KLA is benefiting from the growing demand for AI through its leadership in process control and its ability to address growth markets in wafer fab equipment, including high-bandwidth memory and advanced packaging.
In May 2026, Cohu received approximately $5 million in multiple orders for its Diamond X platform from a leading semiconductor manufacturer. The systems will support testing of next-generation GaN power devices for AI data centers, strengthening Cohu’s position in AI infrastructure and high-efficiency power semiconductor testing.
TER’s Share Price Performance, Valuation and EstimatesTeradyne shares have surged 84.4% in the year-to-date period, outperforming the Zacks Computer & Technology sector’s growth of 18.2% and the Zacks Electronics - Miscellaneous Products increase of 37.5%.
TER Stock Performance
Image Source: Zacks Investment Research
TER stock is trading at a premium with a forward 12-month Price/Sales of 9.75X compared with the Computer & Technology sector’s 6.11X. TER has a Value Score of F.
TER's Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for fiscal 2026 earnings is pegged at $9.10 per share, which has been unchanged over the past 30 days. This suggests 129.80% year-over-year growth.
Teradyne currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Key Takeaways Howmet shares are up 26.5% year to date, beating the S&P 500, its industry and major aerospace peers.Commercial aerospace revenues rose 28% in Q2 as aircraft build rates and engine-spares demand stayed strong.HWM raised 2026 revenue guidance to $10.00-$10.10B, while its 43.79X forward P/E exceeds peers and industry. Howmet Aerospace Inc.’s (HWM - Free Report) shares have surged 26.5% in the year-to-date period, outpacing the S&P 500’s gain of 12.2% and the industry’s 5.4% decline. The advanced engineered solutions provider for the aerospace and transportation industries has also outshone its peers like GE Aerospace (GE - Free Report) and RTX Corporation (RTX - Free Report) , which have returned 9.4% and 9.5%, respectively, over the same time frame.
HWM Outperforms the Industry, S&P 500 & Peers
Image Source: Zacks Investment Research
Closing at $259.27 on Sept. 4, the stock is trading below its 52-week high of $310.00 but significantly higher than its 52-week low of $176.32. The stock is trading below its 50-day moving average but way above its 200-day moving average.
Howmet Shares’ 50-Day and 200-Day SMA
Image Source: Zacks Investment Research
What’s Behind HWM Stock’s Momentum?The strongest driver of Howmet’s business at the moment is the commercial aerospace market. The company is benefiting from solid demand for both narrow and wide-body aircraft, which is supporting higher OEM spending. Pickup in air travel has been positive for the company, as the increased usage of aircraft spurs spending on parts and products that it provides.
Revenues from the commercial aerospace market increased 28% year over year in the second quarter of 2026, following an increase of 20% in the first quarter. The market constituted 53% of its overall business, supported by robust spares demand for engines. Healthy build rates at Airbus for A320 and A350 aircraft, along with a production recovery in the Boeing 737 MAX aircraft, hold promise for HWM’s spare engine demand.
Howmet is also benefiting from persistent strength in the defense aerospace business, cushioned by steady government support. HWM has been experiencing robust orders for engine spares for the F-35 program and other legacy fighters. Revenues from the defense aerospace market increased 11% year over year in the second quarter, constituting 15% of the company’s business.
It's worth noting that the fiscal year 2026 Defense Appropriations Act was signed into law in February 2026, providing a strong budgetary allocation for defense. Such robust provisions set the stage for Howmet, which remains focused on its defense business.
Driven by its business strength, Howmet raised its 2026 revenue outlook to $10.00-$10.10 billion. Adjusted EBITDA is anticipated between $3.21 billion and $3.25 billion, with adjusted earnings projected at $5.23-$5.31 per share.
HWM remains committed to strengthening its business through acquisitions. In April 2026, the company acquired Stanley Black & Decker, Inc.'s (SWK - Free Report) Consolidated Aerospace Manufacturing LLC (“CAM”) business for $1.8 billion. The buyout strengthened HWM’s aerospace fastening solutions portfolio through its established brands, engineering capabilities and deep customer relationships.
Howmet’s measures to reward shareholders are also encouraging. During the first half of the year, HWM distributed $97 million in dividends. In July 2026, it raised its quarterly dividend by 17% to 14 cents per share, equivalent to 56 cents annually. Additionally, through July, the company had repurchased $800 million worth of shares year to date.
Earnings Estimate Revision
Image Source: Zacks Investment Research
Earnings estimates for HWM have moved north over the past 60 days, reflecting analysts’ optimism.
The Zacks Consensus Estimate for 2026 earnings is pegged at $5.26 per share, suggesting year-over-year growth of 5.8%. The consensus mark for 2027 earnings is pinned at $6.22 per share, indicating a year-over-year increase of 5.1%. As earnings estimates increase, the stock is likely to follow suit.
Near-Term ConcernsHowever, Howmet’s shares declined recently after CEO Elon Musk announced that SpaceX intends to begin producing natural gas turbine blades at its Texas facility. This development is likely to bring a new competitive dynamic in the highly specialized turbine blade market, where Howmet has established a strong foothold. Nevertheless, HWM is poised to maintain strong demand momentum moving ahead with growing demand for industrial gas-turbine blades globally.
Stock Valuation
Image Source: Zacks Investment Research
The stock trades at a forward 12-month price-to-earnings (P/E) ratio of 43.79X, higher than the industry average of 30.74X. Also, it is overvalued compared with its peers, GE Aerospace and RTX Corp. Notably, GE Aerospace and RTX Corp. are trading at 39.02X and 26.44X, respectively. This elevated valuation could make the stock vulnerable to further pullbacks if market sentiment sours.
Should You Invest in HWM Stock Now?Persistent strength across both the commercial and defense aerospace markets, supported by strong build rates, spare demand for engines and a high defense budget, positions Howmet favorably for impressive growth in the quarters ahead. Built on a sound liquidity position, HWM’s shareholder-friendly policies also add to its appeal.
Despite its expensive valuation and likely competition from SpaceX in the turbine market, positive analyst sentiment, robust growth prospects and higher annual guidance for revenues and earnings indicate it is the appropriate time for potential investors to bet on this Zacks Rank #2 (Buy) company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the latest close session, Howmet (HWM - Free Report) was down 10.7% at $231.53. This change lagged the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 1.18%, and the technology-centric Nasdaq decreased by 0.32%.
The maker of engineered products for the aerospace and other industries's stock has dropped by 8.61% in the past month, exceeding the Aerospace sector's loss of 10.2% and lagging the S&P 500's loss of 0.36%.
Analysts and investors alike will be keeping a close eye on the performance of Howmet in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $1.34, reflecting a 41.05% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.59 billion, indicating a 23.86% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $5.26 per share and revenue of $10.12 billion, which would represent changes of +39.52% and +22.68%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Howmet. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.38% upward. Howmet is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, Howmet currently has a Forward P/E ratio of 49.29. This indicates a premium in contrast to its industry's Forward P/E of 21.9.
It's also important to note that HWM currently trades at a PEG ratio of 2.37. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Aerospace - Defense was holding an average PEG ratio of 1.65 at yesterday's closing price.
The Aerospace - Defense industry is part of the Aerospace sector. At present, this industry carries a Zacks Industry Rank of 89, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
BP (BP - Free Report) : This integrated energy company, which is engaged in the oil and gas business worldwide, has seen the Zacks Consensus Estimate for its current year earnings increasing 25.4% over the last 60 days.
Crawford & Company (CRD.B - Free Report) : This company, which provides construction and solid waste disposal services principally in Thailand, has seen the Zacks Consensus Estimate for its current year earnings increasing 14.1% over the last 60 days.
Healthcare Services Group (HCSG - Free Report) : This company, which provides housekeeping, laundry, linen, facility maintenance and food services to the health care industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals, has seen the Zacks Consensus Estimate for its current year earnings increasing 12.9% over the last 60 days.
Interface (TILE - Free Report) : This company, which is the world's largest manufacturer of modular carpet, which it markets under the Interface and FLOR brands, has seen the Zacks Consensus Estimate for its current year earnings increasing 11.9% over the last 60 days.
Globus Medical (GMED - Free Report) : This medical device company, that develops and commercializes healthcare solutions for patients with musculoskeletal disorders, has seen the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 day.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
, /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), a Fortune 250 automotive retailer with 249 dealerships located in the U.S. and U.K, today announced the pricing of its private placement of $625.0 million in aggregate principal amount of its 6.250% senior unsecured notes due 2032 (the "2032 Notes") and $625.0 million in aggregate principal amount of its 6.625% senior unsecured notes due 2035 (the "2035 Notes" and, together with the 2032 Notes, the "Notes"). The offering is expected to close on September 22, 2026, subject to customary closing conditions.
The Company intends to use the net proceeds of the offering, together with cash on hand, to fund the purchase price for its previously announced acquisition of certain dealership assets and related real estate from Hennessy Automobile Companies, Inc. and certain of its affiliates (the "Hennessy Acquisition") and to pay related fees and expenses. Because the closing of the Hennessy Acquisition is expected to occur after the closing of the offering, the Company intends to use the net proceeds, pending the closing of the Hennessy Acquisition, to repay a portion of the outstanding borrowings under the acquisition line under its revolving credit facility, which the Company expects to reborrow at the closing of the Hennessy Acquisition to fund a portion of the purchase price.
If the Hennessy Acquisition is not consummated on or prior to the later of (x) January 6, 2027 (the "Outside Date") and (y) such date to which the Outside Date under the purchase agreement relating to the Hennessy Acquisition may be extended in accordance with the terms thereof (such later date, the "Special Mandatory Redemption Outside Date"), or upon the occurrence of certain other events, including the termination of the purchase agreement related to the Hennessy Acquisition prior to the Special Mandatory Redemption Outside Date, the Company will be required to redeem all of the 2032 Notes then outstanding at a redemption price equal to 100% of the initial issue price thereof, plus accrued and unpaid interest, if any, from the issue date to, but excluding, the redemption date (the "Special Mandatory Redemption"). In that case, the Company intends to use the net proceeds of the offering that are not used to fund the Special Mandatory Redemption to repay borrowings under the Company's revolving credit facility and for general corporate purposes.
The Notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and thus, the Notes may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Notes have been offered to persons reasonably believed to be qualified institutional buyers in an offering exempt from registration pursuant to Rule 144A under the Securities Act and to non-U.S. persons outside of the United States in compliance with Regulation S under the Securities Act. This announcement shall not constitute an offer to sell or a solicitation of an offer to buy any of these Notes or any security, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offering, solicitation or sale would be unlawful.
ABOUT GROUP 1 AUTOMOTIVE, INC.
Group 1 owns and operates 249 automotive dealerships, 310 franchises, and 32 collision centers in the United States and the United Kingdom that offer 37 brands of automobiles. Through its dealerships and omni-channel platform, the Company sells new and used cars and light trucks; arranges related vehicle financing; sells service contracts; provides automotive maintenance and repair services; and sells vehicle parts.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which are statements related to future, not past, events and are based on our current expectations and assumptions regarding our business, the economy and other future conditions. In this context, the forward-looking statements include statements regarding the proposed offering, the intended use of proceeds and the pending Hennessy Acquisition. These forward-looking statements often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "should," "foresee," "may" or "will" and similar expressions. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting us will be those that we anticipate. Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause actual results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the impacts of sustained levels of inflation, including reduced affordability of automobiles for consumers, (c) developments in U.S. and global trade policy, including the imposition by the U.S. of significant tariffs on the import of automobiles and certain materials used in our parts and services business and the resulting consequences (including, but not limited to, retaliatory tariffs by non-U.S. nations, supply chain disruptions, vehicle and part cost increases and demand decreases, and potential recessions in the U.S. and U.K.) and the passage of the "One Big Beautiful Bill," including the associated impact on tax deductions in the domestic car industry and the elimination of certain clean energy tax credits, which could impact incentives for electric vehicle production and sales, (d) the level of manufacturer incentives, (e) our ability to comply with extensive laws, regulations and policies applicable to our operations, including BEV mandates in the U.K., and their impact on new vehicle demand, (f) our ability to obtain an inventory of desirable new and used vehicles (including as a result of changes in the international trade environment), (g) our relationship with our automobile manufacturers and the willingness of manufacturers to approve future acquisitions, (h) our cost of financing and the availability of credit for consumers, (i) our ability to complete acquisitions and dispositions, including the pending Hennessy Acquisition, on a timely basis, if at all and the risks associated therewith, (j) our ability to successfully integrate recent and future acquisitions, including the Hennessy Acquisition, and realize the expected benefits from consummated acquisitions, (k) foreign exchange controls and currency fluctuations, (l) the armed conflicts in Ukraine and the Middle East, including that between the U.S. and Iran, (m) broader macroeconomic challenges in the U.K., including inflationary pressures, fluctuations in interest and foreign exchange rates and overall economic volatility, which could further impact vehicle affordability, demand and our financial performance in that market, (n) our ability to maintain sufficient liquidity to operate, and (o) a material failure in or breach of our vendors' information technology systems and other cybersecurity incidents. For additional information regarding known material factors that could cause our actual results to differ from our projected results, please see our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.
Investor contacts:
David Helderman
Senior Manager, Investor Relations
Group 1 Automotive, Inc.
[email protected]
Media contacts:
Pete DeLongchamps
Senior Vice President, Manufacturer Relations, Financial Services and Corporate Development
Group 1 Automotive, Inc.
[email protected]
Kimberly Barta
Head of Advertising, Brand and Communications
Group 1 Automotive, Inc.
[email protected]
DigitalOcean Holdings Inc (DOCN) Stock Up 12.6% but GF Value Says Overvalued -- GF Score: 67/100 On September 08, 2026, DigitalOcean Holdings Inc DOCN shares rose 12.6%, reaching a current price of $126.69. This movement comes amid a 52-week range of $32.35 to $187.50, demonstrating significant volatility and investor interest in the company.
GF Value™ verdict: Current price at $126.69 vs GF Value of $44.59 indicates a 184.1% overvaluation.GF Score™: 67/100, categorizing it as Above Average.Most notable signal: Insiders sold $572.2M worth of shares over the past 12 months without any buying activity.Is DOCN Overvalued or Undervalued?DigitalOcean's current valuation raises concerns, particularly when considering its GF Value™ estimate of $44.59. This proprietary intrinsic-value estimate reflects historical trading multiples, past business growth, and future performance predictions. At its current price, DOCN shares are categorized as significantly overvalued, presenting a 184.1% margin above the GF Value™, signaling potential risks for investors.
The risk associated with investing in a company that is markedly overvalued is exacerbated by the fact that DigitalOcean is currently unprofitable and cash-flow negative. With a high Price-to-Sales (P/S) ratio significantly above its historical median of approximately 5.7x, traditional earnings-based valuation methods such as Price-to-Earnings (P/E) do not apply effectively in this case. Therefore, while the GF Value™ provides a directional warning, it should not be viewed as a precise fair-value target for a loss-making entity like DigitalOcean.
How Does DOCN's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)57.9x45.0xForward P/E68.6xN/AThe current P/E ratio of 57.9x is 28% above its 5-year median of 45.0x, indicating that the stock is trading at a premium compared to its historical valuation metrics. This analysis aligns with the GF Value™ assessment, further substantiating the notion that DigitalOcean is overvalued at its present price level.
What Does DOCN's GF Score™ Tell Us?The GF Score™ provides a holistic view of a company's financial health and competitive positioning by evaluating multiple factors, including financial strength, profitability, growth, valuation, and momentum. DigitalOcean's GF Score™ is currently at 67/100, with its strongest sub-rank being Growth at 10/10, while its weakest is Valuation at 1/10.
MetricRatingGF Score™67Financial Strength5/10Profitability5/10Growth10/10Valuation1/10Momentum3/10Overall, while DigitalOcean exhibits strong growth potential, which is reflected in its perfect Growth rank, its financial strength and valuation metrics suggest significant weaknesses. The low Valuation score particularly underscores concerns regarding its current market price compared to its intrinsic value.
What Are Gurus and Insiders Doing with DOCN?Currently, 6 gurus hold positions in DigitalOcean, with 1 guru adding to their stake and 5 trimming their positions in recent quarters. This mixed activity among institutional investors could indicate a cautious outlook on the stock, especially given the significant insider selling of $572.2M over the past year without any notable buying activity. This trend of selling by insiders may suggest a lack of confidence in the company's near-term prospects and could serve as a warning signal for potential investors.
What This Means for InvestorsIn summary, based on the GF Value™ assessment, DigitalOcean Holdings Inc DOCN is currently overvalued. The company's high P/S ratio and the significant distance between its current stock price and GF Value™ further reinforce this perspective. While the growth potential is present, the valuation metrics and insider selling activity highlight caution for investors considering an entry point into this stock.
For further insights, you can explore the DigitalOcean Holdings Inc DOCN stock page for more details on its financial performance and valuation analysis.
Frequently Asked QuestionsWhat is DOCN's GF Score™?
The GF Score™ for DigitalOcean is 67/100, indicating an above-average assessment of its overall financial health and competitive positioning.
Is DOCN overvalued or undervalued?
DOCN is considered overvalued, with a GF Value™ of $44.59 compared to its current price of $126.69, indicating a significant overvaluation.
What is DOCN's P/E ratio?
The current P/E ratio for DOCN is 57.9x, which is 28% above its 5-year median of 45.0x, suggesting that the stock is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Smartsheet Inc. ("Smartsheet" or the "Company") (NYSE: SMAR) on behalf of sellers of the common stock of Smartsheet between June 1, 2024 and September 23, 2024 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you sold Smartsheet shares during the Class Period, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than October 5, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
The complaint alleges that throughout the Class Period, Smartsheet was repurchasing Smartsheet stock at the same time that Defendants knew that Smartsheet had received a formal acquisition offer from Blackstone Inc. and Vista Equity Partners Management, LLC (the "Consortium") to purchase all outstanding shares of Smartsheet common stock at prices significantly above the then-current market prices of Smartsheet common stock, and therefore significantly above the prices at which Smartsheet was repurchasing Smartsheet common stock from unsuspecting Class members. Further, according to the complaint, Smartsheet had an obligation to disclose that it had received a formal acquisition offer from the Consortium, or abstain from purchasing Smartsheet stock from unsuspecting investors.
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America—the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act—$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Smartsheet, Inc. (“Smartsheet” or the “Company”) (NYSE: SMAR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Smartsheet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until October 5, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Smartsheet securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
A class action lawsuit has been filed, alleging that defendants, throughout the Class Period, failed to disclose material information, which artificially deflated the price of Smartsheet common stock.
On January 24, 2024, Smartsheet received an unsolicited non-public offer from Blackstone Inc. and Vista Equity Partners Management, LLC (together, the “Consortium”) to purchase all the outstanding shares of Smartsheet for $56.25 per share. In April 2024, Smartsheet’s Board of Directors approved a share repurchase program under which Smartsheet could repurchase up to $150 million of its outstanding stock. On July 8, 2024, the Consortium raised its offer to $56.50 per share. Subsequently, on August 21, 2024, the Consortium reiterated its offer to purchase all the outstanding shares of Smartsheet at $56.50 per share. The class action lawsuit alleges that while these offers were on the table and unknown to the investing public, Smartsheet was repurchasing its common stock at market prices significantly below the prices offered by the Consortium. Smartsheet had an obligation to disclose that it had received a formal acquisition offer from the Consortium or abstain from purchasing Smartsheet stock from unsuspecting investors.
During the Class Period (i.e., between June 1, 2024 and September 23, 2024), Smartsheet’s average stock price was $46.45 per share. September 24, 2024, during pre-market hours, Smartsheet disclosed the transaction with the Consortium. The merger eventually closed on January 22, 2025, with the Consortium acquiring Smartsheet for $56.50 per share.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
New York, New York--(Newsfile Corp. - September 8, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of common stock of Smartsheet Inc. (NYSE: SMAR) between June 1, 2024 and September 23, 2024, both dates inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Smartsheet common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Smartsheet class action, go to https://rosenlegal.com/cases/smartsheet-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, on January 24, 2024, Smartsheet received an unsolicited non-public offer from a consortium of investors (the "Consortium") to purchase its outstanding shares for $56.25 per share. In April 2024, Smartsheet's Board of Directors approved a share repurchase program under which Smartsheet could repurchase up to $150 million of its outstanding stock. On July 8, 2024, the Consortium raised its offer to $56.50 per share, and reiterated that offer on August 21, 2024. According to the lawsuit, while these offers were on the table and unknown to the investing public, Smartsheet was repurchasing its common stock at market prices significantly below the prices offered by the Consortium. Smartsheet had an obligation to disclose that it had received a formal acquisition offer from the Consortium or abstain from purchasing Smartsheet stock from unsuspecting investors. During the Class Period, Smartsheet's average stock price was $46.45 per share. On Tuesday, September 24, 2024, during pre-market hours, Smartsheet disclosed the transaction with the Consortium. The merger eventually closed on January 22, 2025, with the Consortium acquiring Smartsheet for $56.50 per share.
To join the Smartsheet class action, go to https://rosenlegal.com/cases/smartsheet-inc-2026/join call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313578
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
The Zacks Instruments – Control industry is well-positioned to benefit from a diligent focus on energy-efficient production processes and integrated software systems. The rising demand for state-of-the-art technology to replace legacy industrial controls with automated products is expected to drive growth.
However, elevated customer inventory levels, high capital expenditures for infrastructure upgrades and intense market volatility may hinder the process automation and instrumentation market. Nevertheless, Sensata Technologies Holding plc (ST - Free Report) and Badger Meter, Inc. (BMI - Free Report) are likely to benefit from strong demand for digital technology, greater emphasis on energy efficiency, cost-reduction initiatives and support for optimal resource utilization.
Industry Description The Zacks Instruments – Control industry comprises manufacturers of precision and specialty motion-control components and systems used in a wide range of industries. These companies deliver sophisticated flow measurement, control and communication solutions for air, water and other forms of gas and liquid used for commercial and residential purposes. The companies offer an array of products for fuel, combustion, fluid, actuation, electronic applications, energy control and optimization, particularly for the process industry. Some industry players offer heating, ventilation and air conditioning products. These include water heaters and electric heating systems for under-floor radiant applications for boiler manufacturers and alternative energy control packages. Few firms provide water reuse products, including drainage and rainwater harvesting solutions.
What's Shaping the Future of Instruments ??? Control Industry Thrust on Optimum Productivity: The industry’s growth is driven mainly by the emphasis on digitized technologies in manufacturing activities, such as the Industrial Internet of Things. The demand for process automation, instrumentation products, safety automation systems and multivariable pressure transmitters for the fast-track manufacturing process is likely to fuel long-term growth opportunities. The use of process instrumentation equipment offers a host of benefits, including improvement in the quality of the product and emission reduction. Therefore, the rapid adoption of technology across various industries and growing regulation and compliance requirements will continue to be major growth drivers. In addition, field instruments play a significant role in process control by measuring the key elements, such as temperature, pressure, flow and level, in process industries such as chemicals, mining and pharmaceuticals. These include transmitters that measure the pressure, flow, temperature, level and humidity of liquids and gases, which are essential for achieving optimum productivity. A differentiated product offering gives greater opportunities for companies to strengthen their market positions.
Price-Sensitive Competition Hurts Margins: Material cost inflation, resulting from constant inflationary pressures, has been affecting industry players’ margins. Transportation costs are also on the rise. Moreover, high raw material prices due to the continued U.S.-Iran conflict, the prolonged Russia-Ukraine war and the consequent economic sanctions against the Putin regime have adversely impacted the production schedules of various firms. While the companies are focused on improving their operating performance, the inability to obtain adequate supplies of raw materials and product parts at favorable prices is likely to hurt businesses. With firms being unable to pass on the entire increase in raw material prices to customers due to stiff competition, profitability is on the wane. High customer inventory levels and a conservative approach toward placing orders for high-value items remain headwinds. Price-sensitive competition for customer retention in the core business is expected to intensify in the coming days. Aggressive competition is likely to limit their ability to attract and retain customers and erode margins. Due to an international footprint, these firms are further exposed to foreign exchange fluctuations that affect their cash flows.
Industrial Automation in Vogue: A greater focus on increased adoption of automation across all industry verticals and higher investments in new technologies are expected to drive growth over the next few years. North America is likely to continue dominating the market in terms of adopting automation. Rising infrastructural investments in the energy and power sector, increasing demand for organic food and nutritional beverages and favorable government policies are aiding growth. The pharmaceutical industry's process automation and instrumentation market is also growing due to low-cost factors and an evolving regulatory environment. Focus on high-quality equipment indicates progressive buyer maturity and willingness to partner with process control industry players.
Zacks Industry Rank Indicates Bullish Trends The Zacks Instruments – Control industry is housed within the broader Zacks Computer and Technology sector. It currently has a Zacks Industry Rank #102, which places it in the top 41% of more than 250 Zacks industries.
The group’s Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates bright near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Before we present a few Instruments Control stocks that you may want to consider for your portfolio, let us take a look at the industry’s recent stock market performance and valuation picture.
Industry Lags S&P 500, Sector The Zacks Instruments – Control industry has lagged the S&P 500 composite and the broader Zacks Computer and Technology sector over the past year.
The industry has jumped 5.2% compared with the S&P 500 and the sector’s growth of 19.5% and 27.1%, respectively.
One-Year Price Performance
Industry???s Current Valuation The Enterprise Value-to-EBITDA (EV/EBITDA) ratio is commonly used for valuing instruments control stocks. The industry has a trailing 12-month EV/EBITDA of 8.97X compared with the S&P 500’s 17.88X. It is also below the sector’s trailing 12-month EV/EBITDA of 19.41X.
Over the past five years, the industry has traded as high as 12.63X and as low as 7.76X, with a median of 9.65X, as the chart below shows.
Trailing 12-Month Enterprise Value-to EBITDA (EV/EBITDA) Ratio
2 Instruments Control Stocks to Watch Sensata: Headquartered in Attleboro, MA, Sensata is a global industrial technology company that develops, manufactures and sells innovative sensor-based solutions. It is considered one of the leading suppliers of electrical protection and power management solutions. The company offers a streamlined set of products, which helps eliminate redundant costs and gives greater pricing flexibility. It invests in cutting-edge technology that enables hybrid and electric vehicles to be more efficient, cost-effective, robust and safe. The company is expanding its electrification ecosystem to facilitate the seamless transition to electric vehicles, aiming to be a leading provider of mission-critical sensor-rich hardware and software solutions. The stock has soared 34.6% in the past year. The Zacks Consensus Estimate for current-year and next-year earnings has been revised upward by 4.7% and 7.1% to $3.77 and $4.07 per share, respectively, since September 2025. It has a long-term earnings growth expectation of 8.9% and delivered an earnings surprise of 3.7%, on average, in the trailing four quarters. It has a VGM Score of A. Sensata carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Price and Consensus: ST
Badger Meter: Headquartered in Milwaukee, WI, the company provides flow measurement, control and communications solutions, serving water and gas utilities, municipalities and industrial customers worldwide. Its products measure water, oil, chemicals and other fluids, and are known for accuracy, long-lasting durability and providing valuable and timely measurement data. With its industry-leading ORION Cellular endpoints, along with communication and software technologies, Badger Meter is focused on creating robust digital solutions to operationalize real-time data into actionable insights. Its BEACON software-as-a-service offering facilitates the collection and analysis of data within the distribution network to improve operational awareness. This Zacks Rank #3 firm has a long-term earnings growth expectation of 9%.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.
#1 (Strong Buy) stocks have produced an unmatched +23.8% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Blue Owl Capital Inc. (OWL - Free Report) Blue Owl Capital Inc. is a global alternative asset manager that deploys private capital across credit, real assets, and GP strategic capital strategies for institutional and private wealth clients. The company is a Delaware corporation formed in May 2021 through the combination of Owl Rock and Dyal Capital, and it has expanded its platform through acquisitions, including Oak Street (2021), Wellfleet (2022), Par Four and CHI (2023), Prima, KAM, Atalaya (2024), and IPI (2025).
OWL is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Finance stock. OWL has a Momentum Style Score of A, and shares are up 0.9% over the past four weeks.
For fiscal 2026, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.01 to $0.88 per share. OWL boasts an average earnings surprise of +2.3%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, OWL should be on investors' short list.
